Ying Han

• Drove the expansion of AmBeed’s North American business in the Building Block markets. • Advised executive management on corporate strategy and future business development initiatives. • Cultivated relationships with enterprise customers to enhance market share and revenue growth. • Provided technical guidance for the success of custom synthesis projects.

𝐅𝐢𝐫𝐦 𝐋𝐞𝐚𝐝𝐞𝐫𝐬𝐡𝐢𝐩 & 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐜 𝐕𝐢𝐬𝐢𝐨𝐧: Founded GreenBioChem LLC to provide elite, science-driven consulting and business development services for the biopharmaceutical sector. Spearhead the firm's overarching strategy, acting as the critical bridge between deep medicinal chemistry and global commercialization. 𝐂𝐫𝐨𝐬𝐬-𝐁𝐨𝐫𝐝𝐞𝐫 𝐃𝐞𝐚𝐥 𝐒𝐭𝐫𝐮𝐜𝐭𝐮𝐫𝐢𝐧𝐠: Lead "East-to-West" Business Development and Search & Evaluation (S&E) initiatives, connecting high-value innovation from the China/Asia biotech ecosystem with top-tier US biopharmaceutical pipelines to facilitate in-licensing, co-development, and strategic investment partnerships. 𝐓𝐚𝐫𝐠𝐞𝐭𝐞𝐝 𝐒𝐞𝐚𝐫𝐜𝐡 & 𝐄𝐯𝐚𝐥𝐮𝐚𝐭𝐢𝐨𝐧 (𝐒&𝐄): Direct the identification and rigorous scientific evaluation of differentiated, IND-enabling through Phase II assets. Core therapeutic focuses include Antibody-Drug Conjugates (ADCs), Targeted Protein Degradation (Molecular Glues & next-gen PROTACs), Synthetic Lethetic Targets , and CNS-related drugs. 𝐒𝐜𝐢𝐞𝐧𝐭𝐢𝐟𝐢𝐜 & 𝐂𝐨𝐦𝐦𝐞𝐫𝐜𝐢𝐚𝐥 𝐃𝐮𝐞 𝐃𝐢𝐥𝐢𝐠𝐞𝐧𝐜𝐞: Serve as the primary scientific and commercial filter for US pharma partners. Leverage 25+ years of medicinal chemistry and computational science expertise to translate complex preclinical/clinical data packages into actionable market intelligence and de-risked investment theses. 𝐓𝐫𝐚𝐧𝐬𝐚𝐜𝐭𝐢𝐨𝐧 𝐋𝐢𝐟𝐞𝐜𝐲𝐜𝐥𝐞 𝐌𝐚𝐧𝐚𝐠𝐞𝐦𝐞𝐧𝐭 & 𝐈𝐏 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐲: Guide domestic biotech innovators through the execution of global partnerships, from initial outreach and NDA implementation to international-standard Virtual Data Room (VDR) structuring, Term Sheet negotiation, and Definitive Agreement execution. Utilize firsthand experience in achieving dual FDA/NMPA IND approvals to align cross-border CMC scale-up and Freedom to Operate (FTO) strategies with MNC expectations.

Founded and scaled a cross-border biotech company focused on targeting "undruggable" proteins via Computer-aided / AI and Targeted Protein Degradation (TPD). Executive Highlights: Company Building: Built a multidisciplinary team of chemists, biologists, and data scientists across US and China operations. Capital Strategy: Served as Chief Fundraiser, securing Series A financing to ensure operational runway. Strategic Alliances: Directed high-value collaborations with global CRO partners to accelerate discovery timelines. Scientific Impact: From Lab to Clinic: Led the Lead Asset (JRD-018) to FDA IND Approval (April 2024). This novel brain-penetrant BET inhibitor validated our platform’s ability to solve complex bioavailability challenges. Platform Innovation: Established a proprietary Computer-aided / AI-medicinal chemistry engine focused on PROTACs and Inhibitors.... Portfolio: Advanced a robust pipeline including KRAS G12D inhibitors/degraders and CDK7 inhibitors to advanced lead stages.

Recruited to lead the R&D transformation of a Top 100 Chinese pharmaceutical enterprise (US FDA & EDQM certified). Served concurrently as General Manager of the subsidiary, Runze Pharmaceutical (Suzhou), managing a 40,000 sq. meter R&D and manufacturing facility. Key Achievements: Organizational Transformation: Built a new R&D center from the ground up, recruiting and managing a multidisciplinary team of over 110 scientists (80 chemists and 30 biologists). Shifted the corporate portfolio strategy from traditional antibiotics/generics toward high-value innovative Oncology and Immunology assets. CRDMO & CDMO Business Leadership: Led the CDMO division with GMP servicing international clients. Oversaw end-to-end service delivery including CMC, finished dosage formulation, QA/QC, and IND-enabling studies, documentation resulting in multiple successful IND filings and approvals. Strategic Business Development: Directed due diligence for global in-licensing opportunities and established strategic collaborations with academic institutions and CROs to accelerate pipeline growth. Operational Excellence: Managed cross-functional operations integrating R&D with pilot and commercial production, ensuring compliance with global quality standards (cGMP).

Organic Chemistry

• led a team leveraging extensive laboratory automation to support eight therapeutic areas, working with the teams at multiple sites. •Accelerated Delivery: By consolidating advanced automation and analytical resources (LCMS, HPLC) into a single high-efficiency hub, we significantly compressed the "Design-Make-Test" cycle for teams across the organization, ensuring faster nomination of clinical candidates. • Contributed to the development of three marketed drugs, multiple clinical compounds and over 20 patents as an inventor.

• Led a team of chemists in developing innovative oncology and diabetes programs (FTEs and FFS) for MNCs. • Utilized a combinatorial compound library approach to accelerate multiple research initiatives. • Prepared competitive bids to secure new business opportunities while mentoring young chemists through daily operations, seminars, posters and publications.

Shanghai Institute of Organic Chemistry